Herceptin 150 mg powder for concentrate for solution for infusion, Enhertu 100 mg powder for concentrate for solution for infusion, Fluorouracil Injection, 50 mg/ml, solution for injection, Ziihera 300 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Xeloda 500 mg film-coated tablets, Xeloda 150 mg film-co

Quick answer

Herceptin 150 mg powder for concentrate for solution for infusion, Enhertu 100 mg powder for concentrate for solution for infusion, Fluorouracil Injection, 50 mg/ml, solution for injection, Ziihera 300 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Xeloda 500 mg film-coated tablets, Xeloda 150 mg film-co for gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma is a Phase 2 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).